FATE - Fate Therapeutics, Inc.
NEXT EARNINGS:
Mar 4, 2026
(in 7 days)
EPS Est: $-0.27
|
Rev Est: $1.2M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$39.50
DETAILS
HIGH:
$145.00
LOW:
$3.00
MEDIAN:
$7.50
CONSENSUS:
$39.50
UPSIDE:
2338.27%
Market Cap:
186.87M
Volume:
3,575,734
Avg Volume:
1,517,895
52 Week Range:
0.66-1.94
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.25
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
181
IPO Date:
2013-10-01
EPS (TTM):
-1.64
P/E Ratio:
-1.01
Revenue (TTM):
13.63M
Total Assets:
440.69M
Total Debt:
85.27M
Cash & Equiv:
36.06M
Rev Growth (5Y):
5.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-48.6%
Debt/Equity:
0.27
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-13 | $-0.27 | $-0.29 | +6.9% | $1.7M | $1.2M | +45.3% |
| 2025-08-12 | $-0.29 | $-0.35 | +17.1% | $1.9M | $1.1M | +66.0% |
| 2025-05-13 | $-0.32 | $-0.39 | +17.9% | $1.6M | $1.2M | +37.5% |
| 2025-03-05 | $-0.31 | $-0.44 | +29.5% | $1.9M | $1.6M | +18.6% |
| 2024-11-12 | $-0.40 | $-0.42 | +4.8% | $3.1M | $1.3M | +132.9% |
| 2024-08-13 | $-0.33 | $-0.47 | +29.8% | $6.8M | $1.4M | +380.3% |
| 2024-05-09 | $-0.47 | $-0.47 | 0.0% | $1.9M | $1.1M | +73.4% |
| 2024-02-26 | $-0.45 | $-0.57 | +21.1% | $1.7M | $1.6M | +5.4% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.63M | 63.53M | 96.30M | 55.85M | 31.43M | 10.68M | 4.74M | 4.11M | 4.40M | 2.43M | 0 | 971,000 |
| Net Income | (186.26M) | (160.93M) | (281.72M) | (212.15M) | (173.39M) | (98.15M) | (66.60M) | (42.95M) | (33.46M) | (29.99M) | (25.88M) | (20.89M) |
| EPS | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -1.07 |
| Total Assets | 440.69M | 506.22M | 705.56M | 921.46M | 622.46M | 302.27M | 213.03M | 105.29M | 95.05M | 67.96M | 51.20M | 55.58M |
| Total Debt | 85.27M | 103.54M | 109.34M | 114.82M | 97.30M | 26.93M | 14.88M | 14.81M | 10.69M | 18.24M | 19.63M | 1.73M |
| Cash & Equivalents | 36.06M | 41.87M | 61.33M | 133.58M | 167.35M | 99.81M | 190.51M | 88.95M | 88.61M | 64.81M | 49.10M | 54.04M |
| Operating Cash Flow | (122.87M) | (132.26M) | (248.21M) | (162.87M) | (39.23M) | (83.17M) | (38.65M) | (36.91M) | (29.82M) | (18.40M) | (22.42M) | (15.37M) |
| Free Cash Flow | (123.60M) | (138.42M) | (283.77M) | (213.57M) | (44.16M) | (90.57M) | (40.95M) | (38.63M) | (30.28M) | (19.89M) | (23.30M) | (15.62M) |
| FCF per Share | -1.09 | -1.41 | -2.93 | -2.25 | -0.54 | -1.33 | -0.73 | -0.92 | -0.95 | -0.78 | -1.14 | -0.80 |
| Book Value | 318.73M | 368.42M | 483.94M | 678.84M | 384.44M | 244.76M | 160.47M | 77.19M | 73.15M | 38.04M | 28.34M | 50.85M |
| Cash & ST Investments | 279.07M | 315.18M | 436.23M | 615.91M | 482.92M | 221.43M | 201.01M | 100.95M | 92.11M | 64.81M | 49.10M | 54.04M |
| ROC Equity | -0.58 | -0.44 | -0.58 | -0.31 | -0.45 | -0.40 | -0.42 | -0.56 | -0.46 | -0.79 | -0.91 | -0.41 |